I'll take the first part of the question.
If we have clear information on what the risks are, then you can have appropriate strategies. You're correct that for different circumstances there would be different strategies. The situation in Canada is more complicated than that because people may enter into a situation around use of opioids from one channel, but then it may be fluid, so that you might be moving from one place to another and, over the course of a single patient, that might change as well. I think that's why we're talking about a multi-pronged, comprehensive strategy, so that we're actually able to address various different factors simultaneously.
In terms of the role of the pharmaceutical companies, certainly they're the ones manufacturing and marketing the products, and they are partly responsible for the way that those are used. But there's also, obviously, the role of the pharmacist, the role of the physicians and the practitioners. That's why you have to address it as, very much as I said, a comprehensive strategy.